Ullrich Bethe

2.9k total citations · 1 hit paper
30 papers, 2.0k citations indexed

About

Ullrich Bethe is a scholar working on Oncology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ullrich Bethe has authored 30 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Infectious Diseases and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ullrich Bethe's work include Colorectal Cancer Treatments and Studies (6 papers), Neutropenia and Cancer Infections (5 papers) and Antifungal resistance and susceptibility (4 papers). Ullrich Bethe is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Neutropenia and Cancer Infections (5 papers) and Antifungal resistance and susceptibility (4 papers). Ullrich Bethe collaborates with scholars based in Germany, Belgium and Spain. Ullrich Bethe's co-authors include Eric Van Cutsem, Michel Praet, Bernard Nordlinger, John Primrose, Meg Finch-Jones, Thomas Gruenberger, Laurence Collette, Rowan W. Parks, Halfdan Sørbye and Philippe Rougier and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

Ullrich Bethe

27 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

2008 1.4k citations Bernard Nordlinger, Halfdan Sørbye et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ullrich Bethe Germany	13	1.5k	1.2k	587	508	163	30	2.0k
Jean‐Christophe Weber France	22	901 0.6×	815 0.7×	781 1.3×	326 0.6×	300 1.8×	60	1.7k
J. Scheele Germany	20	1.6k 1.1×	1.8k 1.5×	1.0k 1.8×	571 1.1×	277 1.7×	61	2.7k
Hervé Perrier France	18	627 0.4×	377 0.3×	522 0.9×	504 1.0×	352 2.2×	63	1.3k
Harmeet Kaur United States	24	1.1k 0.7×	530 0.5×	849 1.4×	508 1.0×	258 1.6×	84	2.1k
Zaed Hamady United Kingdom	20	644 0.4×	523 0.5×	499 0.9×	241 0.5×	108 0.7×	48	1.2k
José M. Enríquez–Navascués Spain	22	766 0.5×	330 0.3×	807 1.4×	242 0.5×	295 1.8×	132	1.6k
Bertrand Suc France	27	1.3k 0.9×	757 0.7×	1.9k 3.2×	886 1.7×	538 3.3×	97	2.8k
S T Fan China	25	522 0.3×	1.0k 0.9×	1.0k 1.8×	454 0.9×	664 4.1×	53	1.9k
Manuel Gallén Spain	17	1.0k 0.7×	235 0.2×	502 0.9×	380 0.7×	206 1.3×	33	1.5k
Yasumasa Takii Japan	21	861 0.6×	215 0.2×	542 0.9×	337 0.7×	68 0.4×	105	1.4k

Countries citing papers authored by Ullrich Bethe

Since Specialization

Citations

This map shows the geographic impact of Ullrich Bethe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ullrich Bethe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ullrich Bethe more than expected).

Fields of papers citing papers by Ullrich Bethe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ullrich Bethe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ullrich Bethe. The network helps show where Ullrich Bethe may publish in the future.

Co-authorship network of co-authors of Ullrich Bethe

This figure shows the co-authorship network connecting the top 25 collaborators of Ullrich Bethe. A scholar is included among the top collaborators of Ullrich Bethe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ullrich Bethe. Ullrich Bethe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bethe, Ullrich, Peter Borchmann, Veronica Di Cristanziano, et al.. (2025). Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study. JMIR Research Protocols. 14. e60675–e60675.

Cornely, Oliver A., et al.. (2025). Revisiting diagnostics: early and accurate diagnosis of invasive fungal infections: a health economic view on investing in innovative diagnostics. Clinical Microbiology and Infection. 31(7). 1089–1091. 1 indexed citations

Salmanton‐García, Jon, Fiona Stewart, Ullrich Bethe, et al.. (2025). Self-testing for 5 respiratory viruses in adult VACCELERATE volunteers in Germany—a pilot study on multi-pathogen rapid antigen testing to monitor community-acquired acute respiratory infections. Frontiers in Public Health. 13. 1638280–1638280.

Bethe, Ullrich, Zoi Dorothea Pana, Christian Drosten, et al.. (2024). Innovative approaches for vaccine trials as a key component of pandemic preparedness – a white paper. Infection. 52(6). 2135–2144. 1 indexed citations

Stemler, Jannik, Antonio J. Carcas, Jesús Frías, et al.. (2022). A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network. Trials. 23(1). 865–865. 2 indexed citations

Stemler, Jannik, Ulrike Wieland, Rosanne Sprute, et al.. (2021). Mobile PCR-based surveillance for SARS-CoV-2 to reduce visiting restrictions in nursing homes during the COVID-19 pandemic: a pilot study. Infection. 50(3). 607–616. 6 indexed citations

Adler, Christoph, et al.. (2017). Rapide Entwicklung eines Hirnödems infolge einer fulminanten Hyponatriämie. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 113(1). 45–49. 1 indexed citations

Vermorken, Jan B., Frédéric Peyrade, John C. Krauss, et al.. (2014). Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Annals of Oncology. 25(3). 682–688. 76 indexed citations

Leblond, Pierre, et al.. (2011). L’inhibiteur d’intégrines Cilengitide : un nouveau principe actif en neuro-oncologie. Bulletin du Cancer. 98(9). 1083–1090. 4 indexed citations

10.

Vermorken, Jan B., J. Guigay, Ricard Mesı́a, et al.. (2011). Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. British Journal of Cancer. 104(11). 1691–1696. 45 indexed citations

11.

Nordlinger, Bernard, Halfdan Sørbye, Bengt Glimelius, et al.. (2008). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. The Lancet. 371(9617). 1007–1016. 1396 indexed citations breakdown →

12.

Köhne, C.-H., Jacques De Grève, J. T. Hartmann, et al.. (2007). Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Annals of Oncology. 19(5). 920–926. 127 indexed citations

13.

Grève, Jacques De, Julia Hartmann, Philippe Vergauwe, et al.. (2006). Capecitabine plus irinotecan versus 5-FU/FA/irinotecan ± celecoxib in first line treatment of metastatic colorectal cancer (CRC). Long-term results of the prospective multicenter EORTC phase III study 40015. Journal of Clinical Oncology. 24(18_suppl). 3577–3577. 25 indexed citations

14.

Rothe, Achim, Michael Seibold, Clemens B. Caspar, et al.. (2004). Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Annals of Hematology. 83(6). 394–397. 46 indexed citations

15.

Wisplinghoff, Hilmar, Oliver A. Cornely, Ullrich Bethe, et al.. (2003). Outcomes of Nosocomial Bloodstream Infections in Adult Neutropenic Patients: A Prospective Cohort and Matched Case-Control Study. Infection Control and Hospital Epidemiology. 24(12). 905–911. 57 indexed citations

16.

Cornely, Oliver A., et al.. (2002). Peripheral Teflon Catheters: Factors Determining Incidence of Phlebitis and Duration of Cannulation. Infection Control and Hospital Epidemiology. 23(5). 249–253. 49 indexed citations

17.

Bethe, Ullrich, et al.. (2002). Treatment for Hepatitis C Virus in Human Immunodeficiency Virus–Infected Patients. Archives of Internal Medicine. 162(22). 2545–2545. 36 indexed citations

18.

Cornely, Oliver A., Ullrich Bethe, Bernd Salzberger, et al.. (2001). Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever. Annals of Hematology. 80(2). 103–108. 9 indexed citations

19.

Cornely, Oliver A., Ullrich Bethe, Harald Seifert, et al.. (2001). A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin. Annals of Hematology. 81(1). 37–43. 12 indexed citations

20.

Cornely, Oliver A., et al.. (2001). A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation. Bone Marrow Transplantation. 28(9). 899–901. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact